Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4%

AC Immune SA (NASDAQ:ACIU) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 796,900 shares, a decline of 7.4% from the September 30th total of 860,900 shares. Based on an average trading volume of 118,700 shares, the short-interest ratio is presently 6.7 days. Currently, 1.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ACIU. Renaissance Technologies LLC grew its holdings in shares of AC Immune by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after purchasing an additional 136,300 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of AC Immune by 294.7% during the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after buying an additional 328,312 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after buying an additional 8,423 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of AC Immune in the 1st quarter valued at $30,000. Finally, Vanguard Capital Wealth Advisors acquired a new stake in shares of AC Immune during the 2nd quarter valued at $56,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on ACIU. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of AC Immune in a report on Wednesday, September 18th. StockNews.com cut shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st.

AC Immune Price Performance

Shares of NASDAQ:ACIU opened at $3.01 on Wednesday. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14. The stock has a market capitalization of $297.69 million, a price-to-earnings ratio of -4.36 and a beta of 1.25. The company’s 50 day simple moving average is $3.29 and its 200 day simple moving average is $3.43.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.67). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million. As a group, analysts anticipate that AC Immune will post -0.89 EPS for the current fiscal year.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.